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Purpose: Enhancer of zeste homolog 2 (EZH2), a kind of
transcriptional repressor, is reportedly over-expressed in
metastatic prostate cancer. In this study, we analyzed EZH2
mRNA in circulating tumor cells (CTCs) in peripheral blood
as a biomarker in patients with metastatic prostate cancer.
Patients and Methods: Ber-EP4 coated immunomagnetic beads
were used to harvest CTCs, and mRNA was isolated by oligo-
dT conjugated immunomagnetic beads. Reverse transcriptase-
polymerase chain reaction for EZH2 mRNA was performed
and the expression density was measured. The sensitivity of
this test for detection of EZH2 mRNA was determined by
serial dilutions of a human prostate cancer cell line. Blood
samples were collected from 20 patients each with metastatic
or localized prostate cancer and 10 healthy volunteers. Results:
Sensitivity experiments showed that the test was highly
sensitive as it could detect 10 tumor cells per 5 mL. EZH2
mRNA expression was obtained from peripheral blood
samples of patients and control subjects. EZH2 mRNA
expression density in the metastatic prostate cancer group was
significantly higher than in the control (p = 0.023) and
localized prostate cancer groups (p = 0.019). There was no
difference between the control and localized prostate cancer
groups (p > 0.05). Conclusion: EZH2 mRNA expression in
circulating epithelial cells represents a promising marker for
detecting early metastasis in prostate cancer. However, more
specific and sensitive techniques for detection of CTCs are
needed to avoid mononuclear cell contamination.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed
male malignancy and the second leading cause of
cancer death in men in the Western world. In
Korea, prostate cancer is the most rapidly
increasing male malignancy by incidence. Although
the introduction of serum prostate specific antigen
(PSA) measurement has allowed early detection of
the disease, clinicians are unable to determine the
potential aggressiveness of individual tumors with
certainty, resulting in the over-or under-treatment
of many patients.
The reverse transcriptase-polymerase chain
reaction (RT-PCR) technique has been used to
search for cells expressing PSA or prostate-specific
membrane antigen in extraprostatic sites, including
the peripheral blood, lymph nodes, and bone
marrow, with various ranges of positivity.
1-10
These
approaches have only limited value, however,
because dissemination of cells is an early event in
prostate cancer that may or may not lead to the
development of metastases.
Enhancer of zeste homolog 2 (EZH2) is a known
repressor of gene transcription. Varambally et al.
first suggested that dysregulated expression of
EZH2 might be involved in the progression of
prostate cancer,11 and Bryant et al. demonstrated
that EZH2 promotes proliferation and invasion of
prostate cancer cells.
12
Recently, Takeshita et al.
showed that the EZH2 small interfering RNA,
which was selected as candidate targets for in-
hibition of bone metastasis, resulted in an efficient
inhibition of metastatic tumor growth in bone
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tissues.13 In this study, we analyzed EZH2 mRNA
in circulating tumor cells (CTCs) in peripheral
blood as a biomarker in patients with metastatic
prostate cancer in order to more clearly elucidate
their metastatic potential.
MATERIALS AND METHODS
Patients and control subjects
Blood samples were collected from 20 patients
each with metastatic prostate cancer and localized
prostate cancer, and 10 healthy volunteers. Metas-
tatic diseases were confirmed by chest X-ray, whole
body bone scan, or computed tomography. Blood
samples of patients with localized prostate cancer
were obtained before radical prostatectomy.
Healthy volunteers were men with normal serum
PSA and normal digital rectal examination. All
patients provided written informed consent.
Characteristics of the subjects are summarized in
Table 1.
Blood samples and immunomagnetic separation
of circulating epithelial cells
Five mL of venous peripheral blood were col-
lected in a heparinized tube and put on ice
immediately. Whole blood was mixed with 10 mL
of phosphate buffered saline (PBS) and the mono-
nuclear cell layer was isolated using AccuspinTM
System-Histopaque -1077 (Sigma-Aldrich
®, St. Louis,
USA) according to the manufacturer’s protocol.
The cell pellet was resuspended in 1 mL of PBS-
2% fetal calf serum (FCS; Invitrogen Corporation,
GibcoTM) and then incubated with 20 million of
prewashed Ber-EP4 monoclonal antibodies for 30
minutes at 4℃ with gentle tilting and rotation
(Dynal Biotech , Oslo, Norway). Dynabeads to
purify epithelial cells are superparamagnetic
polystyrene beads coated with anti-human Ber-
EP4 antibody, directed against the human
epithelial antigen. The rosetted cells were isolated
by placing the tube in a Dynal magnetic particle
concentrator (MPC). The harvested epithelial
cells were then washed five times with PBS-2%
FCS.
Messanger RNA isolation using oligo-
deoxythymidine beads
The Dynabeads mRNA DirectTM Micro kit
(Dynal Biotech ) was used to isolate mRNA from
epithelial cells. The rosetted cells were lysed using
100 L Lysis-binding buffer (Dynal Biotechμ ). The
Table 1. Subject Characteristics
Healthy volunteers Localized prostate ca† Metastatic prostate ca
No. of patients 10 20 20
Age (yrs) 62.0 ± 14.9 64.8 ± 8.3 71.1 ± 6.1
Serum prostate specific antigen level* (ng/mL) 2.1 ± 1.4 11.9 ± 7.9 40.9 ± 48.7
Gleason score
≤ 7
≥ 8
-
-
14
6
8
12
Treatment history
Surgery
Hormonal manipulation
Cytotoxic chemotherapy
-
-
-
18
2
-
-
20
7
Hormonal status
Hormone-sensitive
Hormone-refractory
-
-
-
-
11
9
*At the time of blood sampling.
Blood sampling was performed before treatment.
EZH2 mRNA Expression in Metastatic Prostate Cancer
Yonsei Med J Vol. 48, No. 6, 2007
supernatant was then transferred into a new tube
containing 20 L of pre-washed oligo-dTμ Dyna-
beads and incubated for 5 minutes on a roller at
room temperature. The Dynabeads for oligo-dT
are superparamagnetic beads with covalently
attached oligo-dT. The tube was then placed in
the Dynal MPC, and the supernatant was dis-
carded. The washing step was repeated five times
according tothe manufacturer’s recommenda-
tions. The final suspension was kept on ice prior
to RT-PCR amplification.
RT-PCR for EZH2 mRNA
Ten L of mRNA were reverse transcribed intoμ
cDNA, using a reverse transcription system
(Promega Co., WI, USA) following the supplier’s
recommendations. The 50 L PCR reaction mixtureμ
included 20 L of cDNA, 25μ L Taq PCR Masterμ
Mix Kit (Qiagen, Germany), 5 L of sense primer,μ
and 5 L of anti-sense primer. The EZH2 primersμ
used in this study were described by Varambally
et al.11 Thermocycling conditions included 35
cycles of 94 for 1 minute, 60℃ for 45 sec, and
72℃ for 2 minutes. The entire RT-PCR product
was run on a 2% ethidium bromide-stained agarose
gel, and the image density of EZH2 mRNA
expression was measured by Quantity One
software version 4 (Bio-Rad laboratories, CA,
USA).
Sensitivity experiments
PC3 cells, derived from a patient with hormone
refractory prostate cancer, were used to define
the sensitivity of the assay. These prostatic tumor
cells were mixed with 5 mL of PBS in 10-fold
serial dilutions of 10,000, 1,000, 100, 10, and 1
PC3 cells in 5 mL of PBS. These mixtures were
subjected to the experimental steps previously
described.
Statistical analysis
The Mann-Whitney U test was used to evaluate
differences in image density between study
groups. SPSS for Windows version 12.0 was used
for statistical analyses. P-values were two-sided,
and a p value of less than 0.05 was considered to
be significant.
RESULTS
Immunomagnetic separation and RT-PCR for
EZH2 mRNA was highly sensitive and could
detect 10 tumor cells in 5 mL of PBS (Fig. 1). EZH2
mRNA expression density increased in proportion
to the number of PC3 cells present.
EZH2 mRNA expression was obtained from
peripheral blood samples of healthy volunteers
and patients with localized prostate cancer or
metastatic prostate cancer (Fig. 2). The mean
expression density was 345.7 ± 131.8 intensity/
mm2 in healthy volunteers, 349.4 ± 156.7 intensity
/mm2 in patients with localized prostate cancer,
and 2040.5 ± 1881.3 intensity/mm2 in patients
with metastatic prostate cancer (Fig. 3).
EZH2 mRNA expression density in the metas-
tatic prostate cancer group was significantly
higher than in the control (p = 0.023) and localized
prostate cancer groups (p = 0.019). There was no
difference between the control and localized
Fig. 1. Sensitivity of reverse transcriptase-polymerase
chain reaction for enhancer of zeste homolog 2. The
numbers 1-10,000 indicate the number of PC3 cells in 5 mL
of phosphate buffered saline.
Fig. 2. Representative results of reverse transcriptase-
polymerase chain reaction for enhancer of zeste homolog
2 in peripheral blood samples obtained from healthy
volunteers and patients with localized prostate cancer or
metastatic prostate cancer.
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prostate cancer groups (p > 0.05) (Fig. 3).
DISCUSSION
Current methods for detecting micrometastases
in prostate cancer patients are not satisfactory. For
example, 15% to 40% of men who seem to have
localized disease based on imaging studies and
clinical parameters will instead develop recurrent
disease.14-16 For this reason, identification of CTCs
in peripheral blood is expected to have a
therapeutic or prognostic significance.
CTCs can be detected by PCR amplification of
tumor-specific DNA and mRNA abnormalities
that are present in malignant cells. PCR is more
sensitive than conventional techniques for the
detection of tumor cells and micrometastases,
allowing the identification of 1 tumor cell among
106-107 normal cells.17 In 1992, Moreno et al first
used RT-PCR to detect the presence of PSA
mRNA in peripheral blood specimens of patients
with metastatic prostate cancer.
18
Since then, there
have been numerous reports using this technology
to detect the presence of occult prostate cells in
blood, with CTCs detected in 0 to 72% in patients
with clinically organ-confined disease and 25 to
100% in patients with distant metastases.1-9
However, the major question of the specificity of
the RT-PCR approach remains unanswered due to
the potential for illegitimate transcripts in
lymphocytes or other blood cells.
Interestingly, Ellis et al showed that epithelial
cells express PSA in the bone marrow of 54% of
men with clinically localized disease before radical
prostatectomy.2 This finding is much higher than
the 10% to 30% of patients expected to develop
recurrence after radical prostatectomy. Such
approaches to detect PSA-expressing epithelial
cells have only limited value, because dissemina-
tion of cells is an early event in prostate cancer
that may or may not lead to the development of
metastases.
To overcome these limitations and enhance the
clinical significance of detection of CTCs, new
approaches to enumerate CTCs have been tried.
Moreno et al demonstrated that CTC counts can
be reproducibly measured in patients with hormone
refractory prostate cancer without apparent
diurnal variation, and that the changes in the CTC
levels mirror disease progression.19 Chen et al
further demonstrated that the number of CTCs
reflects current disease status and correlates
significantly with clinical disease indicators.20 On
the other hand, a more specific marker for tumor
progression that is not a prostate-specific may be
more attractive. For example, HER-2/neu in CTCs
of patients with prostate cancer is more frequent
in those with metastases than those with localized
disease.21
To our knowledge, EZH2 has not been used for
detecting CTCs from prostate cancer. In the
present study, we combined immunomagnetic
separation of CTCs with RT-PCR detection of the
EZH2 transcripts to increase the specificity and
better characterize the molecular profile of CTCs.
Gene expression profiling of hormone refractory
metastatic prostate cancer cases has shown that a
high level of expression of the Polycomb Group
gene EZH2 is positively correlated with the pro-
gression of this malignancy in humans.11 Amplifi-
cation of the EZH2 gene occurs in a significant
proportion of advanced hormone refractory
prostate tumors compared to earlier untreated
tumor samples, suggesting a specific role for
EZH2 in disease progression.22 Moreover, patients
with clinically localized prostate cancer that express
high levels of EZH2 are associated with a poorer
Fig. 3. Expression density of reverse transcriptase-
polymerase chain reaction for enhancer of zeste homolog
2 in peripheral blood samples obtained from subjects as
measured by the Quantity One program (*p < 0.05 by
Mann-Whitney U test, compared to the healthy group or
localized prostate cancer group).
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prognosis following radical prostatectomy.11,23 The
role of EZH2 in prostate cancer is still poorly
understood, but a recent study suggests that early
dysregulation of EZH2 in a subset of prostate
cancer cases might promote progression of this
disease from an indolent to an aggressive and
advance phenotype.12
In this preliminary study, we demonstrate a
promising approach to investigate CTCs. Studies
are ongoing to determine how the genotype and
phenotype of isolated disseminated cells differs in
tumors with different metastatic potentials.
Nevertheless, our results have some limitations.
First, a more sensitive technique is needed to
detect CTCs less than 10 in number because tumor
cells in peripheral blood are very rare. Although
EZH2 mRNA was most strongly expressed in
patients with metastatic prostate cancer, it was
also identified in the control and localized prostate
cancer groups. This result may be explained by
mononuclear cell contamination and illegitimate
transcription of EZH2, necessitating more specific
techniques to avoid such contamination. In
addition, further experiments such as real time
RT-PCR are needed for more clear quantification
of EZH2 mRNA expression. Meanwhile, the
clinical significance of EZH2 mRNA expression in
CTCs remains uncertain, and studies with a larger
sample size and long- term follow-up are needed
to fully examine the diagnostic and prognostic
possibilities explored in this study.
In conclusion, EZH2 mRNA in circulating
tumor cells was over-expressed in patients with
metastatic prostate cancer. EZH2 mRNA could be
a promising marker for detecting early metastasis
in prostate cancer, but more specific and sensitive
techniques for the detection of circulating tumor
cells are needed to avoid mononuclear cell
contamination.
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